EDAP TMS Reports Strong Growth and Clinical Advances
Company Announcements

EDAP TMS Reports Strong Growth and Clinical Advances

EDAP TMS (EDAP) has released an update.

EDAP TMS S.A., a leader in robotic energy-based therapies, has reported a 10.6% increase in Q2 2024 total worldwide revenue, achieving EUR 15.8 million, and a 63% growth in U.S. Focal One HIFU procedures year-over-year. The company’s growth is attributed to the expanding adoption of their Focal One technology for prostate cancer treatment, bolstered by positive clinical outcomes and a growing body of clinical evidence suggesting its effectiveness. Additionally, significant corporate developments include executive board changes and the initiation of a Phase 1-2 Clinical Trial for treating Benign Prostate Hyperplasia with Focal One Robotic HIFU.

For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyEDAP TMS price target lowered to $5 from $6 at Piper Sandler
TipRanks Auto-Generated NewsdeskEDAP TMS S.A. Reports Strong Q3 2024 Growth
TipRanks Auto-Generated NewsdeskEDAP TMS Sees Strong Growth and Advances in AI
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App